Distinguished in Multiple Myeloma

Sonja Zweegman

Amsterdam, NH, NL 
Distinguished in Multiple Myeloma
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Sonja Zweegman practices in Amsterdam, Netherlands. Ms. Zweegman is rated as a Distinguished expert by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Multiple Myeloma, Plasmacytoma, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 296 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 186 articles and participated in 1 clinical trial in the study of Multiple Myeloma.

Gender
Female

Locations

Amsterdam, NH, Netherlands
Other Locations
's-hertogenbosch, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

296 Total Publications

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zweegman's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile